Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL982191 | 0.96 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL980803 | 0.89 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL12948871 | 0.86 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL982643 | 0.85 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL984497 | 0.85 | SLC6A2 (0.81) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL984544 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL985282 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL984751 | 0.83 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL980856 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL986505 | 0.81 | SLC6A2 (0.98) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009115427-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | SLC6A2 6/4885SLC6A4 8/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.